☆ 4.4 Review

Is COVID-19-associated cytokine storm distinct from non-COVID-19 secondary hemophagocytic lymphohistiocytosis?

EXPERIMENTAL BIOLOGY AND MEDICINE (2022)

Related references

Note: Only part of the references are listed.

Article Medicine, Research & Experimental

Osteopontin as a biomarker for COVID-19 severity and multisystem inflammatory syndrome in children: A pilot study

Andrew Reisner et al.

Summary: This study suggests that plasma osteopontin (OPN) may serve as a potential biomarker for evaluating the severity of COVID-19 and multisystem inflammatory condition in children (MIS-C). OPN levels were significantly elevated in children with moderate and severe COVID-19 and MIS-C compared to mild/asymptomatic children, and differentiated among clinical severity levels in COVID-19. Future research should focus on the specificity and positive predictive value of OPN as a marker for COVID-19 and MIS-C in children.

EXPERIMENTAL BIOLOGY AND MEDICINE (2022)

Add to Collection

Review Medical Laboratory Technology

Hemophagocytic Lymphohistiocytosis

Tanya Sajan Ponnatt et al.

Summary: Hemophagocytic lymphohistiocytosis (HLH) is a rare and life-threatening disorder of immune regulation that requires rapid diagnosis and aggressive management. Understanding the pathogenesis and early diagnosis of HLH plays a crucial role in determining patient outcome. HLH can be caused by genetic mutations or acquired factors, and proper management is essential for improving prognosis.

ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE (2022)

Add to Collection

Editorial Material Medicine, Research & Experimental

Secondary hemophagocytic lymphohistiocytosis versus cytokine release syndrome in severe COVID-19 patients

Nausheen N. Hakim et al.

Summary: COVID-19 or SARS-CoV-2 infection can lead to severe acute respiratory distress syndrome/pneumonia with cytokine storm resembling secondary hemophagocytic lymphohistiocytosis, which can be diagnosed by the calculated HScore. Although most COVID-19 patients in the study did not meet the diagnostic criteria for HLH, it is hypothesized that identification of HLH may be related to the severity or timing of cytokine release. Distinguishing between cytokine release syndrome and secondary HLH is suggested, with the latter term reserved for cases meeting diagnostic criteria.

EXPERIMENTAL BIOLOGY AND MEDICINE (2021)

Add to Collection

Article Hematology

T-cell activation profiles distinguish hemophagocytic lymphohistiocytosis and early sepsis

Vandana Chaturvedi et al.

Summary: Hemophagocytic lymphohistiocytosis (HLH) is characterized by acute T-cell activation, with CD38(high)/HLA-DR+ effector cells being most pronounced. In contrast, sepsis does not show this distinctive T-cell activation. CD38(high)/HLA-DR+ cells concentration above 7% has strong predictive value for distinguishing HLH from early sepsis or healthy controls.

BLOOD (2021)

Add to Collection

Review Medicine, Research & Experimental

Protease-activated receptor 1 as a potential therapeutic target for COVID-19

Emanuel S. Rovai et al.

Summary: COVID-19, caused by the novel coronavirus SARS-CoV-2, has led to over 1 million deaths worldwide. Clinical symptoms include fever, dry cough, and dyspnea, with a risk of venous thrombosis and pulmonary embolism in severe cases. The disease may lead to a prothrombotic state, characterized by increased thrombin activity and a poor prognosis.

EXPERIMENTAL BIOLOGY AND MEDICINE (2021)

Add to Collection

Review Medicine, Research & Experimental

A mini-review on the effects of COVID-19 on younger individuals

Madhumitha Manivannan et al.

Summary: The COVID-19 pandemic has significantly impacted the world, with young individuals being less affected by the disease but disproportionately impacted by strict lockdown measures.

EXPERIMENTAL BIOLOGY AND MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Tocilizumab in Patients Hospitalized with Covid-19 Pneumonia

Carlos Salama et al.

Summary: Among hospitalized patients with Covid-19 pneumonia not on mechanical ventilation, tocilizumab reduced the risk of progression to mechanical ventilation or death, but did not improve overall survival. There were no new safety concerns identified.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Cell Biology

The efficacy and safety of levilimab in severely ill COVID-19 patients not requiring mechanical ventilation: results of a multicenter randomized double-blind placebo-controlled phase III CORONA clinical study

Nikita Lomakin et al.

Summary: The aim of this study was to evaluate the efficacy and safety of the IL-6 receptor inhibitor levilimab in severe COVID-19 patients, with results showing a significantly higher sustained clinical improvement rate on Day 14 in the LVL treatment group compared to the placebo group. The frequency of adverse drug reactions was comparable between the two groups. The study concluded that the combination of LVL with standard of care resulted in an increase in sustained clinical improvement rate in patients with radiologically confirmed SARS-CoV-2 pneumonia.

INFLAMMATION RESEARCH (2021)

Add to Collection

Editorial Material Medicine, General & Internal

Baricitinib Therapy in Covid-19 Pneumonia - An Unmet Need Fulfilled

Delia Goletti et al.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Article Biochemistry & Molecular Biology

Germline variants in UNC13D and AP3B1 are enriched in COVID-19 patients experiencing severe cytokine storms

Hui Luo et al.

Summary: This study found that PID gene variants, specifically UNC13D and AP3B1, were significantly associated with severe cytokine storms in COVID-19 patients, increasing the risk of fatal outcomes. These genetic variants provide insights into individual susceptibility to severe cytokine storms and can help improve the management of COVID-19.

EUROPEAN JOURNAL OF HUMAN GENETICS (2021)

Add to Collection

Review Medicine, Research & Experimental

COVID-19: Antiviral agents and enzyme inhibitors/receptor blockers in development

Manasi P. Jogalekar et al.

Summary: The outbreak of the 2020 novel coronavirus has caused a significant impact globally, prompting the World Health Organization and several countries to declare a pandemic and state of emergency. In response to COVID-19, various research institutions and pharmaceutical companies are urgently seeking treatments, including repurposing antiviral drugs and developing vaccines.

EXPERIMENTAL BIOLOGY AND MEDICINE (2021)

Add to Collection

Article Rheumatology

Discrimination of COVID-19 From Inflammation-Induced Cytokine Storm Syndromes Using Disease-Related Blood Biomarkers

Christoph Kessel et al.

Summary: This study analyzed the levels of biomarkers in serum samples from patients with COVID-19 and secondary HLH/MAS, and found distinct immune activation patterns between COVID-19 and other cytokine storm syndromes. Serum biomarker profiles could potentially aid in targeting key molecules and pathways associated with systemic cytokine storm conditions in the treatment of COVID-19.

ARTHRITIS & RHEUMATOLOGY (2021)

Add to Collection

Review Medicine, Research & Experimental

SARS-CoV-2 variants: A double-edged sword?

Manasi P. Jogalekar et al.

Summary: Since the outbreak of COVID-19, there have been global concerns about the potential evolution and mutations of the virus leading to increased transmissibility, disease severity, vaccination escape, or even extinction. Rigorous surveillance and research are needed to understand and control the impact of viral variants on the pandemic.

EXPERIMENTAL BIOLOGY AND MEDICINE (2021)

Add to Collection

Article Medicine, General & Internal

Effect of Canakinumab vs Placebo on Survival Without Invasive Mechanical Ventilation in Patients Hospitalized With Severe COVID-19 A Randomized Clinical Trial

Roberto Caricchio et al.

Summary: This clinical trial compared the efficacy of canakinumab vs placebo on survival without invasive mechanical ventilation (IMV) in hospitalized patients with severe COVID-19. The results showed that treatment with canakinumab did not significantly increase the likelihood of survival without IMV compared to placebo.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19 AMeta-analysis

Manu Shankar-Hari et al.

Summary: This study identified 27 clinical trials and found that the use of IL-6 antagonists was associated with lower 28-day all-cause mortality in patients hospitalized for COVID-19 compared to usual care or placebo. Different risk effects were observed between tocilizumab and sarilumab, increasing understanding of the treatment with these drugs.

JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2021)

Add to Collection

Article Medicine, General & Internal

Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia

Patricia O. Guimaraes et al.

Summary: Among patients hospitalized with Covid-19 pneumonia, tofacitinib led to a lower risk of death or respiratory failure through day 28 than placebo. The mortality rate was lower in the tofacitinib group within 28 days. However, the rate of serious adverse events was similar in both groups.

NEW ENGLAND JOURNAL OF MEDICINE (2021)

Add to Collection

Review Cell Biology

Targeting Bruton's Tyrosine Kinase in Inflammatory and Autoimmune Pathologies

Stefan F. H. Neys et al.

Summary: BTK plays a crucial role in B cell development and BCR signaling. Recent studies suggest increased BTK expression in patients with autoimmune diseases, making it a potential target in inflammatory and systemic AID. Inhibition of BTK has shown efficacy in various diseases, with recent reports even indicating its effectiveness in reducing lung inflammation in COVID-19.

FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY (2021)

Add to Collection

Article Hematology

IFN-γ signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS

Howard Lin et al.

Summary: HLH is characterized by pathologic immune activation, and prompt initiation of immune suppression is crucial for survival. Plasma biomarkers can differentiate HLH from other inflammatory conditions, with IFN-gamma signaling uniquely elevated in HLH.

BLOOD ADVANCES (2021)

Add to Collection

Review Biochemistry & Molecular Biology

The signal pathways and treatment of cytokine storm in COVID-19

Lan Yang et al.

Summary: The COVID-19 pandemic is a global crisis with devastating effects, where immunopathology plays a crucial role in disease progression, particularly the cytokine storm which has a significant impact on prognosis. Understanding and targeting the pathways involved in cytokine storm could lead to more effective treatment strategies for COVID-19.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2021)

Add to Collection

Article Hematology

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia

Ning Tang et al.

JOURNAL OF THROMBOSIS AND HAEMOSTASIS (2020)

Add to Collection

Article Hematology

Functional and genetic testing in adults with HLH reveals an inflammatory profile rather than a cytotoxicity defect

Julien Carvelli et al.

BLOOD (2020)

Add to Collection

Article Microbiology

Favorable Anakinra Responses in Severe Covid-19 Patients with Secondary Hemophagocytic Lymphohistiocytosis

George Dimopoulos et al.

CELL HOST & MICROBE (2020)

Add to Collection

Review Medicine, Research & Experimental

Novel 2019 coronavirus: Genome structure, clinical trials, and outstanding questions

Manasi P. Jogalekar et al.

EXPERIMENTAL BIOLOGY AND MEDICINE (2020)

Add to Collection

Review Medicine, Research & Experimental

The amount of cytokine-release defines different shades of Sars-Cov2 infection

S. Bindoli et al.

EXPERIMENTAL BIOLOGY AND MEDICINE (2020)

Add to Collection

Article Allergy

Ruxolitinib in treatment of severe coronavirus disease 2019 (COVID-19): A multicenter, single-blind, randomized controlled trial

Yang Cao et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Allergy

Plasma IP-10 and MCP-3 levels are highly associated with disease severity and predict the progression of COVID-19

Yang Yang et al.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)

Add to Collection

Article Pathology

SARS-CoV-2 Infection-Associated Hemophagocytic Lymphohistiocytosis: An Autopsy Series With Clinical and Laboratory Correlation

Andrey Prilutskiy et al.

AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2020)

Add to Collection

Review Immunology

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

Dennis McGonagle et al.

AUTOIMMUNITY REVIEWS (2020)

Add to Collection

Review Medicine, Research & Experimental

Pathology and pathogenicity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Henok Kessete Afewerky

EXPERIMENTAL BIOLOGY AND MEDICINE (2020)

Add to Collection

Review Medicine, Research & Experimental

Role of inflammatory markers in corona virus disease (COVID-19) patients: A review

Jyoti Upadhyay et al.

EXPERIMENTAL BIOLOGY AND MEDICINE (2020)

Add to Collection

Letter Hematology

Secondary HLH is uncommon in severe COVID-19

Henry Wood et al.

BRITISH JOURNAL OF HAEMATOLOGY (2020)

Add to Collection

Article Immunology

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

Mark Roschewski et al.

SCIENCE IMMUNOLOGY (2020)

Add to Collection

Review Infectious Diseases

The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19

Qing Ye et al.

JOURNAL OF INFECTION (2020)

Add to Collection

Article Multidisciplinary Sciences

Title: Cytokine release syndrome is not usually caused by secondary hemophagocytic lymphohistiocytosis in a cohort of 19 critically ill COVID-19 patients

Georg Lorenz et al.

SCIENTIFIC REPORTS (2020)

Add to Collection

Review Medicine, General & Internal

Cytokine Storm

David C. Fajgenbaum et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Medicine, Research & Experimental

Baricitinib restrains the immune dysregulation in patients with severe COVID-19

Vincenzo Bronte et al.

JOURNAL OF CLINICAL INVESTIGATION (2020)

Add to Collection

Article Hematology

Recommendations for the management of hemophagocytic lymphohistiocytosis in adults

Paul La Rosee et al.

BLOOD (2019)

Add to Collection

Article Oncology

CD163 as a valuable diagnostic and prognostic biomarker of sepsis-associated hemophagocytic lymphohistiocytosis in critically ill children

Yun Cui et al.

PEDIATRIC BLOOD & CANCER (2019)

Add to Collection

Article Medicine, General & Internal

Hemophagocytic lymphohistiocytosis in adults: An under recognized entity

Abdul Rashid Shah et al.

BBA CLINICAL (2017)

Add to Collection

Article Multidisciplinary Sciences

A Web-Based Delphi Study for Eliciting Helpful Criteria in the Positive Diagnosis of Hemophagocytic Syndrome in Adult Patients

Gilles Hejblum et al.

PLOS ONE (2014)

Add to Collection

Article Rheumatology

Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome

Laurence Fardet et al.

ARTHRITIS & RHEUMATOLOGY (2014)

Add to Collection

Review Immunology

Molecular mechanisms of biogenesis and exocytosis of cytotoxic granules

Genevieve de Saint Basile et al.

NATURE REVIEWS IMMUNOLOGY (2010)

Add to Collection

© Peeref 2019-2024. All rights reserved.